Capricor Therapeutics’ (CAPR) Overweight Rating Reiterated at Cantor Fitzgerald

Key Takeaways:

• Cantor Fitzgerald restated its ‘overweight’ rating on Capricor Therapeutics.
• A $30.00 price objective was set for the company’s stock.
• FY2025 earnings are estimated at $1.71 EPS by Cantor Fitzgerald.
• The research report was distributed on Wednesday morning.
• The report’s details were covered by Benzinga.

Cantor Fitzgerald Reaffirms ‘Overweight’ Rating

Cantor Fitzgerald has restated its ‘overweight’ rating on shares of Capricor Therapeutics (NASDAQ: CAPR), according to a research report sent to investors on Wednesday morning. This reaffirmation signals the brokerage firm’s continued confidence in the biotechnology company’s potential performance and growth prospects.

$30 Price Objective Set

In the latest analysis, Cantor Fitzgerald set a price objective of $30.00 for Capricor Therapeutics’ stock. This target suggests a significant upside from current market prices, indicating that the stock may be undervalued and presenting a potentially lucrative opportunity for investors.

Positive Earnings Forecast for FY2025

Alongside the rating and price target, Cantor Fitzgerald issued an earnings estimate for Capricor Therapeutics, projecting $1.71 earnings per share (EPS) for the fiscal year 2025. This optimistic earnings forecast reflects expectations of robust financial performance and successful operational milestones in the coming years.

Report Highlighted by Benzinga

The details of Cantor Fitzgerald’s research report were highlighted by Benzinga, a reputable financial news outlet. The coverage by Benzinga helps disseminate the information to a broader audience, emphasizing the importance of the brokerage firm’s analysis and its impact on investor sentiment.

Continued Confidence in Capricor Therapeutics

The reaffirmation of the ‘overweight’ rating and the positive financial projections underscore Cantor Fitzgerald’s continued confidence in Capricor Therapeutics. Investors and market observers may view this as a strong vote of confidence, potentially influencing investment decisions and market dynamics surrounding the company’s stock.